REGENERON PHARMAC.DL-,001/ US75886F1075 /
5/21/2024 8:16:38 AM | Chg. +2.0000 | Volume | Bid12:53:08 PM | Ask12:53:08 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
901.2000EUR | +0.22% | 0 Turnover: 0.0000 |
898.6000Bid Size: 10 | 909.6000Ask Size: 10 | 100.2 bill.EUR | - | - |
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/8
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
4/29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
4/25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
4/24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
4/22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
4/7
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
4/1
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire
3/13
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...
GlobeNewswire
3/11
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...
GlobeNewswire
3/8
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...
GlobeNewswire
2/23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
2/21
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Re...
GlobeNewswire
2/16
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
2/2
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
2/2
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
1/30
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platf...